Search Results - "WHITTEN, JEFFREY" :: K.UTB vyhledávací portál | TBU Library Retrieval Portal

Anticancer Activity of CX-3543: A Direct Inhibitor of rRNA Biogenesis

Anticancer Activity of CX-3543: A Direct Inhibitor of rRNA Biogenesis

by DRYGIN, Denis, SIDDIQUI-JAIN, Adam, LIM, John K. C, VON HOFF, Daniel, ANDERES, Kenna, RICE, William G, O'BRIEN, Sean, SCHWAEBE, Michael, LIN, Amy, BLIESATH, Josh, HO, Caroline B, PROFFITT, Chris, TRENT, Katy, WHITTEN, Jeffrey P
Published in Cancer research (Chicago, Ill.) (01.10.2009)

Get full text

Journal Article

Discovery and SAR of 5-(3-Chlorophenylamino)benzo[c][2,6]naphthyridine-8-carboxylic Acid (CX-4945), the First Clinical Stage Inhibitor of Protein Kinase CK2 for the Treatment of Cancer

Discovery and SAR of 5-(3-Chlorophenylamino)benzo[c][2,6]naphthyridine-8-carboxylic Acid (CX-4945), the First Clinical Stage Inhibitor of Protein Kinase CK2 for the Treatment of Cancer

by Pierre, Fabrice, Chua, Peter C, O’Brien, Sean E, Siddiqui-Jain, Adam, Bourbon, Pauline, Haddach, Mustapha, Michaux, Jerome, Nagasawa, Johnny, Schwaebe, Michael K, Stefan, Eric, Vialettes, Anne, Whitten, Jeffrey P, Chen, Ta Kung, Darjania, Levan, Stansfield, Ryan, Anderes, Kenna, Bliesath, Josh, Drygin, Denis, Ho, Caroline, Omori, May, Proffitt, Chris, Streiner, Nicole, Trent, Katy, Rice, William G, Ryckman, David M
Published in Journal of medicinal chemistry (27.01.2011)

Get full text

Journal Article

Pre-clinical characterization of CX-4945, a potent and selective small molecule inhibitor of CK2 for the treatment of cancer

Pre-clinical characterization of CX-4945, a potent and selective small molecule inhibitor of CK2 for the treatment of cancer

by Pierre, Fabrice, Chua, Peter C., O’Brien, Sean E., Siddiqui-Jain, Adam, Bourbon, Pauline, Haddach, Mustapha, Michaux, Jerome, Nagasawa, Johnny, Schwaebe, Michael K., Stefan, Eric, Vialettes, Anne, Whitten, Jeffrey P., Chen, Ta Kung, Darjania, Levan, Stansfield, Ryan, Bliesath, Joshua, Drygin, Denis, Ho, Caroline, Omori, May, Proffitt, Chris, Streiner, Nicole, Rice, William G., Ryckman, David M., Anderes, Kenna
Published in Molecular and cellular biochemistry (01.10.2011)

Get full text

Journal Article

Discovery of CX-5461, the First Direct and Selective Inhibitor of RNA Polymerase I, for Cancer Therapeutics

Discovery of CX-5461, the First Direct and Selective Inhibitor of RNA Polymerase I, for Cancer Therapeutics

by Haddach, Mustapha, Schwaebe, Michael K, Michaux, Jerome, Nagasawa, Johnny, O'Brien, Sean E, Whitten, Jeffrey P, Pierre, Fabrice, Kerdoncuff, Pauline, Darjania, Levan, Stansfield, Ryan, Drygin, Denis, Anderes, Kenna, Proffitt, Chris, Bliesath, Josh, Siddiqui-Jain, Adam, Omori, May, Huser, Nanni, Rice, William G, Ryckman, David M
Published in ACS medicinal chemistry letters (12.07.2012)

Get full text

Journal Article

Discovery of CX-6258. A Potent, Selective, and Orally Efficacious pan-Pim Kinases Inhibitor

Discovery of CX-6258. A Potent, Selective, and Orally Efficacious pan-Pim Kinases Inhibitor

by Haddach, Mustapha, Michaux, Jerome, Schwaebe, Michael K, Pierre, Fabrice, O’Brien, Sean E, Borsan, Cosmin, Tran, Joe, Raffaele, Nicholas, Ravula, Suchitra, Drygin, Denis, Siddiqui-Jain, Adam, Darjania, Levan, Stansfield, Ryan, Proffitt, Chris, Macalino, Diwata, Streiner, Nicole, Bliesath, Joshua, Omori, May, Whitten, Jeffrey P, Anderes, Kenna, Rice, William G, Ryckman, David M
Published in ACS medicinal chemistry letters (09.02.2012)

Get full text

Journal Article

Determination of the importance of the stereochemistry of psorospermin in topoisomerase II–induced alkylation of DNA and in vitro and in vivo biological activity

Determination of the importance of the stereochemistry of psorospermin in topoisomerase II–induced alkylation of DNA and in vitro and in vivo biological activity

by Fellows, Ingrid M, Schwaebe, Michael, Dexheimer, Thomas S, Vankayalapati, Hariprasad, Gleason-Guzman, Mary, Whitten, Jeffrey P, Hurley, Laurence H
Published in Molecular cancer therapeutics (01.11.2005)

Get full text

Journal Article

Design and Synthesis of a Series of Non-Peptide High-Affinity Human Corticotropin-Releasing Factor1 Receptor Antagonists

Design and Synthesis of a Series of Non-Peptide High-Affinity Human Corticotropin-Releasing Factor1 Receptor Antagonists

by Chen, Dagnino, Raymond, De Souza, Errol B, Grigoriadis, Dimitri E, Huang, Charles Q, Kim, Kyung-Il, Liu, Zhengyu, Moran, Terry, Webb, Thomas R, Whitten, Jeffrey P, Xie, Yun Feng, McCarthy, James R
Published in Journal of medicinal chemistry (25.10.1996)

Get full text

Journal Article

Nickel(0)-catalyzed coupling of vinylzirconiums to α-bromo-α,α-difluoro esters. Convenient generation of a functionalized allyldifluoro moiety

Nickel(0)-catalyzed coupling of vinylzirconiums to α-bromo-α,α-difluoro esters. Convenient generation of a functionalized allyldifluoro moiety

by Schwaebe, Michael K, McCarthy, James R, Whitten, Jeffrey P
Published in Tetrahedron letters (05.02.2000)

Get full text

Journal Article

Design, synthesis, and SAR of 2-dialkylamino-4-arylpyrimidines as potent and selective corticotropin-releasing factor1 (CRF1) receptor antagonists

Design, synthesis, and SAR of 2-dialkylamino-4-arylpyrimidines as potent and selective corticotropin-releasing factor1 (CRF1) receptor antagonists

by HUANG, Charles Q, GRIGORIADIS, Dimitri E, ZHENGYU LIU, MCCARTHY, James R, RAMPHAL, John, WEBB, Thomas, WHITTEN, Jeffrey P, XIE, Michael Y, CHEN CHEN
Published in Bioorganic & medicinal chemistry letters (03.05.2004)

Get full text

Journal Article

Rapid Microscale Synthesis, a New Method for Lead Optimization Using Robotics and Solution Phase Chemistry: Application to the Synthesis and Optimization of Corticotropin-Releasing Factor1 Receptor Antagonists

Rapid Microscale Synthesis, a New Method for Lead Optimization Using Robotics and Solution Phase Chemistry: Application to the Synthesis and Optimization of Corticotropin-Releasing Factor1 Receptor Antagonists

by Whitten, Jeffrey P, Xie, Yun Feng, Erickson, Philip E, Webb, Thomas R, De Souza, Errol B, Grigoriadis, Dimitri E, McCarthy, James R
Published in Journal of medicinal chemistry (25.10.1996)

Get full text

Journal Article

Abstract 1319: Repotrectinib, a new generation ROS1 inhibitor, is highly potent against fusion ROS1s and emerging resistance mutations

Abstract 1319: Repotrectinib, a new generation ROS1 inhibitor, is highly potent against fusion ROS1s and emerging resistance mutations

by Deng, Wei, Zhai, Dayong, Zhang, Xin, Lee, Dong, Rogers, Evan, Whitten, Jeffrey, Cui, J. Jean
Published in Cancer research (Chicago, Ill.) (01.07.2019)

Get full text

Journal Article

Abstract 4796: Ropotrectinib is a novel polypharmacology kinase inhibitor against WT and mutant ROS1, TRK and ALK

Abstract 4796: Ropotrectinib is a novel polypharmacology kinase inhibitor against WT and mutant ROS1, TRK and ALK

by Deng, Wei, Zhai, Dayong, Huang, John, Rogers, Evan, Whitten, Jeffrey, Lim, John, Li, Yishan, Cui, Jean
Published in Cancer research (Chicago, Ill.) (01.07.2018)

Get full text

Journal Article

CRAC 채널 억제제의 합성

CRAC 채널 억제제의 합성

by ROGERS EVAN, WHITTEN JEFFREY P, DUNN MICHAEL, STAUDERMAN KENNETH A
Year of Publication 13.01.2022

Get full text

Patent

Abstract 2133: Ending the endless acquired tyrosine kinase resistance mutations — Design of TPX-0005, a multi-target ALK/ROS1/TRK inhibitor with broad spectrum activity against wild-type and mutants including ALK G1202R, ROS1 G2032R and TRKA G595R

Abstract 2133: Ending the endless acquired tyrosine kinase resistance mutations — Design of TPX-0005, a multi-target ALK/ROS1/TRK inhibitor with broad spectrum activity against wild-type and mutants including ALK G1202R, ROS1 G2032R and TRKA G595R

by Cui, J. Jean, Rogers, Evan, Zhai, Dayong, Deng, Wei, Huang, Zhongdong, Whitten, Jeffrey, Li, Yishan
Published in Cancer research (Chicago, Ill.) (15.07.2016)

Get full text

Journal Article

Abstract 2133: Ending the endless acquired tyrosine kinase resistance mutations Design of TPX-0005, a multi-target ALKROS1TRK inhibitor with broad spectrum activity against wild-type and mutants including ALK G1202R, ROS1 G2032R and TRKA G595R

Abstract 2133: Ending the endless acquired tyrosine kinase resistance mutations Design of TPX-0005, a multi-target ALKROS1TRK inhibitor with broad spectrum activity against wild-type and mutants including ALK G1202R, ROS1 G2032R and TRKA G595R

by Cui, JJean, Rogers, Evan, Zhai, Dayong, Deng, Wei, Huang, Zhongdong, Whitten, Jeffrey, Li, Yishan
Published in Cancer research (Chicago, Ill.) (15.07.2016)

Get full text

Journal Article

Abstract B186: TPX-0005, a polypharmacology inhibitor, overcomes ALK treatment resistance from acquired mutations, bypass signaling, and EMT

Abstract B186: TPX-0005, a polypharmacology inhibitor, overcomes ALK treatment resistance from acquired mutations, bypass signaling, and EMT

by Zhai, Dayong, Deng, Wei, Rogers, Evan, Huang, Zhongdong, Whitten, Jeffrey, Lim, John, Li, Yishan, Cui, J. Jean
Published in Molecular cancer therapeutics (01.01.2018)

Get full text

Journal Article

Abstract B185: TPX-0005, a supreme ROS1 inhibitor, overcomes crizotinib-resistant ROS1 mutations including solvent front mutation G2032R and gatekeeper mutation L2026M

Abstract B185: TPX-0005, a supreme ROS1 inhibitor, overcomes crizotinib-resistant ROS1 mutations including solvent front mutation G2032R and gatekeeper mutation L2026M

by Cui, J. Jean, Zhai, Dayong, Deng, Wei, Rogers, Evan, Huang, Zhongdong, Whitten, Jeffrey, Lim, John, Li, Yishan
Published in Molecular cancer therapeutics (01.01.2018)

Get full text

Journal Article

Abstract B184: TPX-0005, a highly potent TRK inhibitor, effectively overcomes clinical-resistance TRK mutations including solvent front mutants TRKA G595R, TRKB G639R, and TRKC G623R

Abstract B184: TPX-0005, a highly potent TRK inhibitor, effectively overcomes clinical-resistance TRK mutations including solvent front mutants TRKA G595R, TRKB G639R, and TRKC G623R

by Cui, J. Jean, Zhai, Dayong, Deng, Wei, Rogers, Evan, Huang, Zhongdong, Whitten, Jeffrey, lim, John, Li, Yishan
Published in Molecular cancer therapeutics (01.01.2018)

Get full text

Journal Article

Abstract 1321: TPX-0022, a polypharmacology inhibitor of MET/CSF1R/SRC for treatment of cancers with abnormal HGF/MET signaling

Abstract 1321: TPX-0022, a polypharmacology inhibitor of MET/CSF1R/SRC for treatment of cancers with abnormal HGF/MET signaling

by Zhai, Dayong, Rogers, Evan, Deng, Wei, Zhang, Xin, Lee, Dong, Ung, Jane, Zhang, Han, Liu, Jing, Lu, Yuelie, Huang, John, Graber, Armin, Zimmerman, Zach, Lim, John, Whitten, Jeffrey, Cui, J. Jean
Published in Cancer research (Chicago, Ill.) (01.07.2019)

Get full text

Journal Article

Abstract 1325: TPX-0022, a polypharmacology inhibitor of MET/CSF1R/SRC inhibits tumor growth by promoting anti-tumor immune responses

Abstract 1325: TPX-0022, a polypharmacology inhibitor of MET/CSF1R/SRC inhibits tumor growth by promoting anti-tumor immune responses

by Deng, Wei, Zhai, Dayong, Rogers, Evan, Zhang, Xin, Lee, Dong, Ung, Jane, Zhang, Han, Liu, Jing, Lu, Yuelie, Huang, John, Graber, Armin, Zimmerman, Zach, Lim, John, Whitten, Jeffrey, Cui, J. Jean
Published in Cancer research (Chicago, Ill.) (01.07.2019)

Get full text

Journal Article

1
2
3
4
5
6
7
8
9
10
11
Next
[20]